Pre-made Enoblituzumab benchmark antibody ( Whole mAb, anti-CD276 therapeutic antibody, Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Enoblituzumab biosimilar, Whole mAb, Anti-CD276 Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Enoblituzumab is a monoclonal antibody designed for the treatment of cancer. Formerly known as MGA271, the drug is a humanized IgG1¦Ê monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.
| Products Name (INN Index) | Pre-Made Enoblituzumab biosimilar, Whole mAb, Anti-CD276 Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 therapeutic antibody |
|---|---|
| INN Name | Enoblituzumab |
| Target | CD276 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2017 |
| Companies | MacroGenics,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Conditions Approved | NA |
| Conditions Active | Prostate cancer,Solid tumours,Head and neck cancer |
| Conditions Discontinued | Malignant melanoma,Non-small cell lung cancer,Squamous cell cancer,Urogenital cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD276 |
| Package |
